Neurological conditions such as traumatic brain injury, stroke, Parkinson's disease, epilepsy, multiple sclerosis, and Alzheimer's disease are serious clinical problems that affect millions of people worldwide. The majority of clinical trials for these common conditions have failed, and there is a critical need to understand why treatments in preclinical animal models do not translate to patients. Many patients with these conditions are middle-aged or older, however, the majority of preclinical studies have used only young-adult animals. Considering that aging involves biological changes that are relevant to the pathobiology of neurological diseases, the lack of aged subjects in preclinical research could contribute to translational failures. This paper details how aging affects biological processes involved in neurological conditions, and reviews aging research in the context of traumatic brain injury, stroke, Parkinson's disease, epilepsy, multiple sclerosis, and Alzheimer's disease. We conclude that aging is an important, but often overlooked, factor that influences biology and outcomes in neurological conditions, and provide suggestions to improve our understanding and treatment of these diseases in aged patients.

中文翻译：

---

需要将成年动物纳入神经系统疾病的临床前模型中。

诸如创伤性脑损伤，中风，帕金森氏病，癫痫，多发性硬化症和阿尔茨海默氏病等神经系统疾病是严重的临床问题，影响着全球数百万人。针对这些常见情况的大多数临床试验都失败了，因此迫切需要了解为什么临床前动物模型中的治疗方法无法转化为患者。许多患有这些疾病的患者是中年或更高年龄，但是，大多数临床前研究仅使用成年动物。考虑到衰老涉及与神经疾病病理生物学相关的生物学变化，因此临床前研究中缺乏衰老的受试者可能会导致翻译失败。本文详细介绍了衰老如何影响涉及神经系统疾病的生物过程，并在脑外伤，中风，帕金森氏病，癫痫，多发性硬化症和阿尔茨海默氏病的背景下回顾了衰老研究。我们得出结论，衰老是影响神经系统疾病的生物学和结局的重要因素，但常常被忽略，并提供建议以增进我们对老年患者对这些疾病的了解和治疗。